Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+H3, —N+H2X, —N+HX2, or —N+HX3, wherein each X is independently —CH3 or —C2H5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radiolabel.

Abstract: Disclosed are methods, kits, polypeptides, and pharmaceutical compositions for inducing an immune response in a subject, which may include a T-cell mediated immune response. The methods comprise administering to the subject, or to explanted cells of the subject, a pharmaceutical composition comprising an effective amount of versikine or a variant of versikine that induces the T-cell mediated immune response. The methods, kits, polypeptides, and pharmaceutical compositions may be used, in particular, to treat a subject having a cell proliferative disease or disorder.

Abstract: It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R2 is —N+H3, —N+H2X, —N+HX2, or —N+HX3, wherein each X is independently —CH3 or —C2H5. The compounds can be used to treat multiple myeloma or to detect multiple myeloma. In therapeutic treatment, R1 includes a radionuclide that locally delivers therapeutic dosages of radiation to the multiple myeloma tumors cells that preferentially take up the compound. In detection/imaging applications, R1 includes a detection moiety, such as a fluorophore or a radiolabel.